Community Financial Services Group LLC Sells 236 Shares of Novartis AG (NYSE:NVS)

Community Financial Services Group LLC trimmed its holdings in shares of Novartis AG (NYSE:NVS) by 0.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 53,952 shares of the company’s stock after selling 236 shares during the period. Community Financial Services Group LLC’s holdings in Novartis were worth $5,250,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in NVS. Centaurus Financial Inc. raised its holdings in Novartis by 1.7% during the third quarter. Centaurus Financial Inc. now owns 5,728 shares of the company’s stock worth $659,000 after purchasing an additional 98 shares in the last quarter. FLC Capital Advisors raised its position in shares of Novartis by 4.4% during the 3rd quarter. FLC Capital Advisors now owns 2,366 shares of the company’s stock worth $272,000 after purchasing an additional 100 shares during the last quarter. Clear Harbor Asset Management LLC lifted its holdings in Novartis by 2.3% in the 3rd quarter. Clear Harbor Asset Management LLC now owns 4,423 shares of the company’s stock valued at $509,000 after purchasing an additional 100 shares in the last quarter. Allen Wealth Management LLC lifted its position in Novartis by 1.8% during the third quarter. Allen Wealth Management LLC now owns 5,788 shares of the company’s stock worth $666,000 after buying an additional 100 shares during the period. Finally, WealthPlan Investment Management LLC lifted its holdings in shares of Novartis by 1.1% during the 3rd quarter. WealthPlan Investment Management LLC now owns 9,494 shares of the company’s stock worth $1,092,000 after acquiring an additional 100 shares during the period. Hedge funds and other institutional investors own 13.12% of the company’s stock.

Novartis Trading Up 0.8 %

NVS stock opened at $107.73 on Wednesday. Novartis AG has a twelve month low of $92.35 and a twelve month high of $120.92. The company has a market cap of $220.20 billion, a P/E ratio of 18.32, a PEG ratio of 1.70 and a beta of 0.58. The company has a quick ratio of 0.90, a current ratio of 1.04 and a debt-to-equity ratio of 0.48. The business has a fifty day moving average of $100.36 and a 200-day moving average of $108.37.

Novartis (NYSE:NVS) last posted its quarterly earnings data on Friday, January 31st. The company reported $1.98 earnings per share for the quarter, topping the consensus estimate of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. As a group, equities research analysts expect that Novartis AG will post 8.42 EPS for the current year.

Analyst Upgrades and Downgrades

NVS has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft upgraded Novartis from a “hold” rating to a “buy” rating in a research note on Tuesday, February 4th. HSBC lowered shares of Novartis from a “hold” rating to a “reduce” rating in a research note on Wednesday, December 4th. Erste Group Bank reiterated a “hold” rating on shares of Novartis in a report on Tuesday, November 19th. StockNews.com upgraded shares of Novartis from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, BMO Capital Markets raised their target price on Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a research note on Wednesday, October 30th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $123.38.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.